This discovery, which is published in the Biochemical Journal, may explain the low incidence of many cancers (with the exception of melanoma) in patients with Parkinson’s disease and could lead the way to carbidopa being repurposed as an anticancer medication. Read more . . .
Research shows the Parkinson’s disease drug carbidopa displays significant anticancer effects in both human cell lines and mice when given at normal patient dosage levels.